Document is current
Any future updates will be listed below
-
Authors
Crepaldi, Maria Cristina
Vedovato, Monica
Morieri, Mario Luca
Basso, Giovanni
Stefanelli, Lucia Federica
Alessi, Marianna
Fioretto, Paola
Fadini, Gian Paolo https://orcid.org/0000-0002-6510-2097
- License Information
-
More Information
Article History
Received: 9 March 2026
Accepted: 14 May 2026
First Online: 30 May 2026
Declarations
Conflict of Interest: Mario Luca Morieri received honoraria or speaker fees from Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Guidotti, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi, and Servier. Paola Fioretto received fees as consultant and speaker for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. Gian Paolo Fadini received honoraria for consultancy, advisory boards or lectures from AstraZeneca, Boehringer, Lilly, Novartis, Novo Nordisk, Sanofi. Maria Cristina Crepaldi, Monica Vedovato, Giovanni Basso, Lucia Federica Stefanelli, and Marianna Alessi have nothing to disclose. Gian Paolo Fadini is an Editorial Board member of Diabetes Therapy . Gian Paolo Fadini was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
Ethical Approval: The study was approved by the Ethics Committee of The University Hospital of Padova (CET ACEV, prot 422n/AO/2) and conducted in accordance with the Helsinki Declaration of 1964, and its later amendments. All participants signed written informed consent. Patients signed written informed consent for their data to be used in the protocol referred to in the text, which covers the analysis presented in the manuscript.
